The present invention is concerned with antibody-drug conjugates (ADCs) for use in cancer immunotherapy. The invention provides an ADC in combination with an immunotherapy (IMT) agent for use in cancer treatment. For example: The invention provides an ADC for use in cancer immunotherapy, wherein...
Antibody drug conjugates (ADCs) are becoming critical new weapons in the war against cancer. Ahead of December's Global Healthcare Conference, Citi Research kicks off a series of looks at healthcare innovations with an overview of ADCs, which combine the
Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the potency of highly cytotoxic agents, potentially reducing the severity of side effects by preferentially targeting their payload to the tumour site. ADCs are being increasingly used in combination with other agents,...
Journal of Experimental & Clinical Cancer Research https://doi.org/10.1186/s13046-023-02868-x (2023) 42:280 Journal of Experimental & Clinical Cancer Research REVIEW Open Access Antibody drug conjugates: hitting the mark in pancreatic cancer? Nicole L. Wittwer1,2* , Michael P. Brown1,2...
Unlocking the potential of antibody–drug conjugates for cancer therapy Introduction Cancer has become the second greatest global health threat, accounting for approximately 10.0 million deaths from cancer occurred in 2020.1Cytotoxic agents based chemotherapy has been the main approach for the treatment of...
Antibody-drug conjugatesbladder cancerurothelial cancerIntroduction The therapeutic landscape for urothelial carcinoma has changed significantly over the past few years with the addition of immunotherapy to platinum-based chemotherapy. Targeted therapy against FGFR (fibroblast growth factor receptor) is now ...
2. Tsuchikama, K., Anami, Y., Ha, S.Y.Y. et al. Exploring the next generation of antibody–drug conjugates. Nat Rev Clin Oncol 21, 203–223 (2024). https://doi.org/10.1038/s41571-023-00850-2 Featured Products Complement Proteins: A New Dawn in Immunotherapy ...
Antibody-drug conjugates are for people whose multiple myeloma hasn't improved with other treatments or has come back after they've tried a few different treatments. To be a good candidate for an antibody-drug conjugate, you need to have taken at least four of these immunotherapy medicines firs...
cough, increased aspartate aminotransferase, and nausea, all of which were mostly mild or moderate (grade 1 or 2), in addition to corneal events and thrombocytopenia, which are consistent with the known toxic effects of other MMAF-linked antibody–drug conjugates8 and were found to be manageable...
Dr Porter stated that the data “underscores the potential benefits of combining antibody drug conjugates with immunotherapies for this patient group.” Assessing efficacy of the antibody drug conjugate-immunotherapy combination There were 16 patients enrolled in the first stage of the clinical...